Table 3.
Genotype and allelic distribution of the rs8720 and rs12587 variants of the KRAS gene in CRC patients and a control group.
| Variants | CRC | Controls * | OR | 95%(CI) | p Value | ||||
|---|---|---|---|---|---|---|---|---|---|
| rs8720 | Model | Genotype | (n = 385) | % | (n = 310) | % | |||
| TT | (88) | 23 | (74) | 24 | 1.0 | ||||
| Codominant | TC | (151) | 39 | (155) | 50 | 0.64 | (0.47–0.87) | 0.005 | |
| CC | (146) | 38 | (81) | 26 | 1.72 | (1.24–2.39) | 0.001 | ||
| Dominant | TT | (83) | 22 | (137) | 28 | ||||
| TC + CC | (294) | 78 | (355) | 72 | 1.05 | (0.74–1.50) | 0.753 | ||
| Recessive | CC | (145) | 38 | (112) | 23 | 1.72 | (1.24–2.39) | 0.001 | |
| TT + TC | (232) | 62 | (380) | 77 | |||||
| Alleles | (2n = 770) | (2n = 620) | |||||||
| T | (327) | 0.4246 | (303) | 0.4887 | 0.77 | (0.62–0.95) | 0.019 | ||
| C | (443) | 0.5754 | (317) | 0.5113 | 1.29 | (1.04–1.60) | 0.019 | ||
| rs12587 | Genotypes | (n = 383) | % | (n = 282) | % | ||||
| TT | (110) | 29 | (86) | 30 | 1.0 | ||||
| Codominant | TG | (165) | 43 | (137) | 49 | 0.80 | (0.58–1.09) | 0.183 | |
| GG | (108) | 28 | (59) | 21 | 1.48 | (1.03–2.13) | 0.040 | ||
| Dominant | TT | (110) | 29 | (86) | 30 | ||||
| TG + GG | (273) | 71 | (196) | 70 | 1.08 | (0.78–1.52) | 0.619 | ||
| Recessive | GG | (108) | 25 | (59) | 25 | 1.48 | (1.03–2.13) | 0.040 | |
| TT + TG | (275) | 75 | (223) | 75 | |||||
| Alleles | (2n = 766) | (2n = 564) | |||||||
| T | (385) | 0.5026 | (309) | 0.5478 | 0.83 | (0.67–1.03) | 0.114 | ||
| G | (381) | 0.4974 | (255) | 0.4522 | 1.19 | (0.96–1.49) | 0.114 | ||
OR (odds ratio), CI (confidence intervals, p value adjusted (significant < 0.05). * Hardy–Weinberg equilibrium (HWE) for the control group: variants rs8720 (chi-square test = 0.045; p =0.830), and rs12587 (chi-square test = 0.0804, p = 0.77).